Funding for this research was provided by:
Novo Nordisk Inc (N/A)
Received: 13 May 2020
Accepted: 23 October 2020
First Online: 10 November 2020
Ethics approval and consent to participate
: Approval was obtained from relevant ethics committees, and written consent was obtained from all participants or guardians/legal representatives. ANSWER was conducted in accordance with the Declaration of Helsinki, Guideline for Good Pharmacoepidemiology Practices, and regulatory requirements.
: Not applicable.
: MA has nothing to disclose. MJA has received research support from AstraZeneca. She also serves as a research investigator for Novo Nordisk, Ascendis, Soleno, Levo, Millendo, and Rhythm; as a speaker for Novo Nordisk and Rhythm; and as an advisory board member for Ascendis and Rhythm. AP, VO, and NK are employees of Novo Nordisk. MT is an advisory board member for Novo Nordisk, Pfizer, Ipsen, and Merck Serono, a consultant for Alizé Pharma, a recipient of grants from Novo Nordisk, Pfizer, Ipsen, and Sandoz, a research investigator for Novo Nordisk and Alizé Pharma, and a speaker for Novo Nordisk, Pfizer, Ipsen, and Merck Serono.